消胀利水方外敷联合肝病治疗仪治疗顽固性腹水31例

Xiaozhang Lishui prescription combined with therapeutic instrument for liver disease in treating of refractory ascites

目的观察自拟消胀利水方配合肝病治疗仪对肝硬化顽固性腹水的临床疗效及可能的作用机制。方法 62例肝硬化顽固性腹水患者随机分为治疗组和对照组各31例。对照组采用常规的保肝利尿及补充白蛋白治疗,治疗组在此基础上加用自拟消胀利水方外敷配合肝病治疗仪,2次/d,30 min/次,2组均治疗1个月。治疗前后分别观察2组患者临床疗效及肝功能指标。结果治疗组临床疗效总有效率90.3%,对照组为83.9%,2组比较差异有统计学意义(P<0.05)。治疗后2组谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)均较治疗前降低,而白蛋白(ALB)升高(P<0.05);2组治疗后比较,治疗组ALT、TBIL均低于对照组(P<0.05)。结论消胀利水方外敷联合肝病治疗仪可活血行气、利水消胀。

Objective To observe the effect and possible mechanism of Xiaozhang Lishui prescription combined with therapeutic Instrument for liver disease refractory ascites with liver cirrhosis. Methods The 62 cases of cirrhosis with refractory ascites were randomly divided into treatment group 31 cases and control group of 31 cases. The control group using conventional treatment of protecting liver,diuresis and supplement albumin. The treatment group was additionally given external application of Xiaozhang Lishui prescription with therapeutic Instrument for liver disease,twice daily,every half an hour,the two groups were treated in January. Before and after treatment,the clinical effect and liver function indexes of the two groups were observed. Results The total effective rate of the treatment group was 90. 3%,and the control group was 83. 9%,the difference between the two groups was statistically significant（ P〈0. 05）. After treatment,two groups of alanine aminotransferase（ ALT） and aspartate aminotransferase（ AST）,total bilirubin（ TBIL） were significantly lower than before treatment,but albumin（ ALB） increased（ P〈0. 05）; After treatment,the treatment group ALT and TBIL were lower than those in the control group（ P〈0. 05）. Conclusion Xiaozhang Lishui prescription combined with therapeutic instrument for liver disease can promote blood circulation and qi circulation,. Xiaozhang Lishui.